Print Email Facebook Twitter Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection Title Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection Author van Dijk, Bruce (University Medical Center Utrecht) Oliveira, Sabrina (Universiteit Utrecht) Hooning van Duyvenbode, J. Fred F. (University Medical Center Utrecht) Nurmohamed, F. Ruben H.A. (University Medical Center Utrecht) Mashayekhi, Vida (Universiteit Utrecht) Beltran Hernandez, Irati (Universiteit Utrecht) van Strijp, Jos (University Medical Center Utrecht) de Vor, Lisanne (University Medical Center Utrecht) Aerts, Piet C. (University Medical Center Utrecht) Vogely, H. Charles (University Medical Center Utrecht) Weinans, Harrie (TU Delft Biomaterials & Tissue Biomechanics; University Medical Center Utrecht) van der Wal, Bart C.H. (University Medical Center Utrecht) Date 2024 Abstract Introduction Implant infections caused by Staphylococcus aureus are responsible for high mortality and morbidity worldwide. Treatment of these infections can be difficult especially when bacterial biofilms are involved. In this study we investigate the potential of infrared photoimmunotherapy to eradicate staphylococcal infection in a mouse model. Methods A monoclonal antibody that targets Wall Teichoic Acid surface components of both S. aureus and its biofilm (4497-IgG1) was conjugated to a photosensitizer (IRDye700DX) and used as photoimmunotherapy in vitro and in vivo in mice with a subcutaneous implant pre-colonized with biofilm of Staphylococcus aureus. A dose of 400 μg and 200 μg of antibody-photosensitizer conjugate 4497-IgG–IRDye700DXwas administered intravenously to two groups of 5 mice. In addition, multiple control groups (vancomycin treated, unconjugated IRDye700DX and IRDye700DX conjugated to a non-specific antibody) were used to verify anti-microbial effects. Results In vitro results of 4497-IgG-IRDye700DX on pre-colonized (biofilm) implants showed significant (p<0.01) colony-forming units (CFU) reduction at a concentration of 5 μg of the antibody-photosensitizer conjugate. In vivo, treatment with 4497-IgG-IRDye700DX showed no significant CFU reduction at the implant infection. However, tissue around the implant did show a significant CFU reduction with 400 μg 4497-IgG-IRDye700DX compared to control groups (p = 0.037). Conclusion This study demonstrated the antimicrobial potential of photoimmunotherapy for selectively eliminating S. aureus in vivo. However, using a solid implant instead of a catheter could result in an increased bactericidal effect of 4497-IgG-IRDye700DX and administration locally around an implant (per operative) could become valuable applications in patients that are difficult to treat with conventional methods. We conclude that photoimmunotherapy could be a potential additional therapy in the treatment of implant related infections, but requires further improvement. To reference this document use: http://resolver.tudelft.nl/uuid:72bb8f0a-579b-4454-ac27-dfd86c544bef DOI https://doi.org/10.1371/journal.pone.0300069 ISSN 1932-6203 Source PLoS ONE, 19 (3) Part of collection Institutional Repository Document type journal article Rights © 2024 Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H.A. Nurmohamed, Vida Mashayekhi, Irati Beltran Hernandez, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C.H. van der Wal Files PDF journal.pone.0300069.pdf 1.01 MB Close viewer /islandora/object/uuid:72bb8f0a-579b-4454-ac27-dfd86c544bef/datastream/OBJ/view